CONDUENT Inc — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that CONDUENT Inc filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.04B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $3.36B | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $3.72B | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $3.86B | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $4.14B | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | $4.16B | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $4.47B | Feb 23, 2022 |
| FY2017 | Dec 31, 2017 | $6.02B | Mar 1, 2018 |
| FY2017 | Dec 31, 2016 | $6.41B | Mar 1, 2018 |
| FY2017 | Dec 31, 2015 | $6.66B | Mar 1, 2018 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.04B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $3.36B | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $3.72B | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $3.86B | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $4.14B | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | $4.16B | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $4.47B | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | $5.39B | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $6.02B | Feb 27, 2020 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $5.98B | Mar 1, 2018 |
| FY2017 | Dec 31, 2016 | $6.36B | Mar 1, 2018 |
| FY2017 | Dec 31, 2015 | $6.61B | Mar 1, 2018 |
| FY2016 | Dec 31, 2014 | $6.88B | Mar 10, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $1.05B | Mar 1, 2018 |
| FY2017 | Dec 31, 2016 | $910.00M | Mar 1, 2018 |
| FY2017 | Dec 31, 2015 | $685.00M | Mar 1, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $426.00M | Feb 19, 2025 |
| FY2024 | Dec 31, 2023 | ($296.00M) | Feb 19, 2025 |
| FY2024 | Dec 31, 2022 | ($182.00M) | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | ($28.00M) | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | ($118.00M) | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | ($1.93B) | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | ($416.00M) | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $181.00M | Feb 27, 2020 |
| FY2017 | Dec 31, 2016 | ($983.00M) | Mar 1, 2018 |
| FY2017 | Dec 31, 2015 | ($414.00M) | Mar 1, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Dec 31, 2015 | $104.00M | Mar 10, 2017 |
| FY2016 | Dec 31, 2014 | $74.00M | Mar 10, 2017 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.00M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $6.00M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $7.00M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $7.00M | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $4.00M | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | $1.00M | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $8.00M | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | $11.00M | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $12.00M | Feb 27, 2020 |
| FY2017 | Dec 31, 2016 | $31.00M | Mar 1, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $412.00M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $455.00M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $458.00M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $440.00M | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $544.00M | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | $468.00M | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $479.00M | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | $560.00M | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $611.00M | Feb 27, 2020 |
| FY2017 | Dec 31, 2016 | $686.00M | Mar 1, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($73.00M) | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | ($50.00M) | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $89.00M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $144.00M | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $243.00M | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | $161.00M | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $132.00M | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | $283.00M | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $300.00M | Feb 27, 2020 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $59.00M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $28.00M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $51.00M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $92.00M | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $80.00M | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | $76.00M | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $148.00M | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | $179.00M | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $96.00M | Feb 27, 2020 |
| FY2017 | Dec 31, 2016 | $149.00M | Mar 1, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.40B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $2.60B | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $3.16B | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | $3.57B | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | $4.04B | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | $4.26B | Feb 23, 2022 |
| FY2020 | Dec 31, 2019 | $4.51B | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | $6.68B | Feb 27, 2020 |
| FY2017 | Dec 31, 2017 | $7.55B | Mar 1, 2018 |
| FY2017 | Dec 31, 2016 | $7.71B | Mar 1, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.57B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $1.61B | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $2.39B | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | $2.51B | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | $2.76B | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | $2.92B | Feb 23, 2022 |
| FY2020 | Dec 31, 2019 | $3.07B | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | $3.32B | Feb 27, 2020 |
| FY2017 | Dec 31, 2017 | $3.88B | Mar 1, 2018 |
| FY2017 | Dec 31, 2016 | $4.28B | Mar 1, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $685.00M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $839.00M | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $629.00M | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | $917.00M | Feb 21, 2024 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $617.00M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $609.00M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $651.00M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $955.00M | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $1.34B | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | $1.53B | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $1.50B | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | $3.41B | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $3.37B | Feb 27, 2020 |
| FY2017 | Dec 31, 2016 | $3.89B | Mar 1, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($2.61B) | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | ($2.43B) | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | ($2.85B) | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | ($2.54B) | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | ($2.35B) | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | ($2.31B) | Feb 23, 2022 |
| FY2020 | Dec 31, 2019 | ($2.19B) | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | ($233.00M) | Feb 27, 2020 |
| FY2017 | Dec 31, 2017 | $171.00M | Mar 1, 2018 |
| FY2017 | Dec 31, 2016 | $0 | Mar 1, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $233.00M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $366.00M | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $498.00M | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | $582.00M | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | $415.00M | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | $450.00M | Feb 23, 2022 |
| FY2020 | Dec 31, 2019 | $496.00M | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | $756.00M | Feb 27, 2020 |
| FY2017 | Dec 31, 2017 | $658.00M | Mar 1, 2018 |
| FY2017 | Dec 31, 2016 | $390.00M | Mar 1, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | 2 | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | (1) | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | (9) | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | (2) | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | 0 | Feb 27, 2020 |
| FY2017 | Dec 31, 2016 | (4) | Mar 1, 2018 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | 2 | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | (1) | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | (9) | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | (2) | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | 0 | Feb 27, 2020 |
| FY2017 | Dec 31, 2016 | (4) | Mar 1, 2018 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 154.71M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | 161.83M | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | 211.51M | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | 218.35M | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | 215.38M | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | 212.07M | Feb 23, 2022 |
| FY2020 | Dec 31, 2019 | 211.51M | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | 211.31M | Feb 27, 2020 |
| FY2017 | Dec 31, 2017 | 210.44M | Mar 1, 2018 |
| FY2017 | Dec 31, 2016 | 202.88M | Mar 1, 2018 |